1. Inicio
  2. Publicaciones
  3. Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Aix, SP
  • Talbot, D
  • Govindan, R
  • Dols, MC
  • Postmus, PE
  • Lewanski, C
  • Bennouna, J
  • Fischer, JR
  • Stewart, DJ
  • Ardizzoni, A
  • Bhore, R
  • Wolfsteiner, M
  • Reck, M
  • Ong, TJ
  • Morgensztern, D

Grupos

Abstract

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

Datos de la publicación

ISSN/ISSNe:
1479-6694, 1744-8301

Future Oncology  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
749-762
PubMed:
32228198
Factor de Impacto:
0,857 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • durvalumab; EORTC QLQ-C30; EQ-5D-5L; lung cancer symptom scale; nab-paclitaxel; non-small cell lung cancer; quality of life

Campos de Estudio

Cita

Compartir